News Releases

RNS Number : 1277O MaxCyte, Inc. 06 October 2021   TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN US57777K1060 Issuer Name   MAXCYTE, INC.   UK or Non- UK Issuer Non- UK   2. Reason for Notification An acquisition or disposal of voting rights; An acquisition or

RNS Number : 8000N MaxCyte, Inc. 01 October 2021     MaxCyte, Inc. (" MaxCyte " or the "Company") Notice of Annual General Meeting   Change of Director   Gaithersburg, Maryland - 1 October 2021 :       MaxCyte, Inc ( NASDAQ: MXCT; LSE: MXCT, MXCN ), a leading commercial cell - engineering company

RNS Number : 7698N MaxCyte, Inc. 01 October 2021     MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights   Gaithersburg, Maryland - 1 October 2021 :       MaxCyte, Inc ( NASDAQ: MXCT; LSE: MXCT, MXCN ), a leading commercial cell - engineering company focused on providing enabling

RNS Number : 1652M MaxCyte, Inc. 17 September 2021   MaxCyte Set to Join Russell 2000® Index GAITHERSBURG, MD , September 16, 2021   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance

GAITHERSBURG, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,

RNS Number : 6380L MaxCyte, Inc. 14 September 2021         MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections   GAITHERSBURG, MD , September 13, 2021   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell

RNS Number : 6377L MaxCyte, Inc. 14 September 2021         MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2021   GAITHERSBURG, MD , September 13, 2021   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on

GAITHERSBURG, Md., Sept. 13, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,

RNS Number : 8949K MaxCyte, Inc. 06 September 2021           MaxCyte, Inc. (" MaxCyte " or the "Company")     Issue of Equity   Increase to Block Listing   Block Listing Return   and   Total Voting Rights       GAITHERSBURG, MD , September 6, 2021   - MaxCyte, Inc.

RNS Number : 5833K MaxCyte, Inc. 02 September 2021   MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021   GAITHERSBURG, MD , September 02, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell